GlassScriptPhysician profile
Darya Belyayeva
NPI 1265160683
$3,616.46
in general payments reported to CMS, 2019-2025
23 companies · $1,297 in 2025
The $1,297 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $675 · 2023: $704 · 2024: $940 · 2025: $1,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,941.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $477.23 | 2023-2025 | Rexulti, Nuedexta |
| Novo Nordisk INC | $474.93 | 2022-2023 | Wegovy |
| Abbvie INC. | $300.65 | 2023-2025 | |
| Eisai INC. | $244.64 | 2025 | |
| Averitas Pharma INC. | $150.47 | 2025 | Qutenza |
| Teva Pharmaceuticals USA, INC. | $145.06 | 2023 | Austedo, Austedo Xr |
| Abbott Laboratories | $140.60 | 2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $135.77 | 2024 | Spravato |
| Ucb, INC. | $131.09 | 2024 | Nayzilam, Briviact |
| Lundbeck LLC | $124.99 | 2022 | |
| Kyowa Kirin, INC. | $124.94 | 2025 | |
| Astellas Pharma US INC | $124.92 | 2023 | Veozah |
| Xeris Pharmaceuticals, INC. | $121.83 | 2025 | Recorlev |
| Mylan Specialty L.P. | $120.68 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $112.50 | 2025 | Wainua |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $111.84 | 2024 | Auvelity |
| Inspire Medical Systems, INC. | $111.60 | 2024 | Inspire |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $97.64 | 2025 | |
| Dexcom, INC. | $89.97 | 2024 | Dexcom G7 Gss (161) |
| Vertex Pharmaceuticals Incorporated | $87.77 | 2025 | |
| Paratek Pharmaceuticals, INC. | $86.78 | 2023 | Nuzyra |
| Spark Therapeutics, INC. | $78.90 | 2022 | |
| Neurocrine Biosciences, INC. | $21.66 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darya Belyayeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.